#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17636	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2173	807.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1463	1463	C	1052	C	980	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32730	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3590	908.8	0	.	n	.	0	T695C	SNP	695	695	T	1091	1091	C	1028	C	951	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32730	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3590	908.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1733	1733	A	1079	A,G	1011,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32730	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3590	908.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2367	2367	C	1052	C,T,G	971,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32730	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3590	908.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2441	2441	A	1006	A	960	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32730	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3590	908.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2993	2993	C	988	C,T,A	926,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2304	folP	852	852	100.0	folP.l15.c4.ctg.1	1533	149.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1031	1033	AGC	231;227;231	A;G;C	217;216;217	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3317	175.3	1	SNP	p	S91F	0	.	.	271	273	TCC	580	582	TCC	203;203;206	T;C;C	185;189;187	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3317	175.3	1	SNP	p	D95G	0	.	.	283	285	GAC	592	594	GAC	202;204;204	G;A;C	184;186;185	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3317	175.3	1	SNP	p	D95N	0	.	.	283	285	GAC	592	594	GAC	202;204;204	G;A;C	184;186;185	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1956	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1287	150.9	1	SNP	p	G45D	0	.	.	133	135	GGC	523	525	GGC	248;250;251	G;G;C	231;231;233	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	994	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1007	98.3	0	.	n	.	0	A197.	DEL	197	197	A	586	586	A	237	A	226	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6064	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2875	209.9	1	SNP	p	D86N	0	.	.	256	258	GAC	553	555	GAC	218;219;218	G;A;C	206;204;204	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6064	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2875	209.9	1	SNP	p	S87W	0	.	.	259	261	AGT	556	558	AGT	218;220;221	A;G;T	205;208;208	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6064	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2875	209.9	1	SNP	p	S87R	0	.	.	259	261	AGT	556	558	AGT	218;220;221	A;G;T	205;208;208	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6064	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2875	209.9	1	SNP	p	S87I	0	.	.	259	261	AGT	556	558	AGT	218;220;221	A;G;T	205;208;208	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6064	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2875	209.9	1	SNP	p	S88P	0	.	.	262	264	TCC	559	561	TCC	221;220;219	T,C;C;C	208,1;206;207	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4888	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2635	184.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1598	1600	GGC	230;229;229	G;G;C	212;207;206	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1227	1229	GCA	262;267;267	G;C;A	240;245;247	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1230	1232	ATC	269;270;271	A;T;C	248;248;248	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1242	1244	GTG	263;265;264	G;T;G	245;241;243	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1242	1244	GTG	263;265;264	G;T;G	245;241;243	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1746	1748	ACC	238;236;240	A;C;C	218;215;221	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1800	1802	GCG	221;224;227	G;C;G	191;171;185	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1800	1802	GCG	221;224;227	G;C;G	191;171;185	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1923	1925	GGC	190;189;190	G;G;C	177;177;175	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1932	1934	GGC	187;184;184	G;G;C	174;169;172	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4740	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2340	201.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1950	1952	CCG	169;167;164	C,CGG;C,G;GCCC,GGGCCCC	116,1;115,1;101,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6750	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3048	220.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2722	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1850	146.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	531	531	C	183	C	167	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	397	399	GGA	309;312;315	G;G,A;A	286;286,2;289	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	658	660	CTT	264;266;269	C;T;T	245;248;252	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	682	684	GGA	255;255;255	G;G;A	239;238;234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	820	822	AGC	243;243;244	A;G;C	219;220;222	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	.	MULTIPLE	619	621	AAA	874	879	TACTAC	227;226;229;232;228;227	T;A;C;T;A;C	221;218;221;225;217;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	K208M	NONSYN	622	624	AAA	881	883	ATG	222;224;219	A;T;G	216;216;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	.	MULTIPLE	628	630	GAA	887	890	AAAC	214;214;215;213	A;A;A;C	206;207;206;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	N212Y	NONSYN	634	636	AAT	895	897	TAT	215;219;216	T;A;T	210;213;209	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	I214M	NONSYN	640	642	ATC	901	903	ATG	224;226;225	A;T;G	211;215;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	L218F	NONSYN	652	654	CTT	913	915	TTT	226;220;221	T;T;T	214;210;210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	A238V	NONSYN	712	714	GCC	973	975	GTT	240;239;240	G;T;T	224;221;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	T252A	NONSYN	754	756	ACA	1015	1017	GCA	233;234;231	G;C;A	212;210;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	W253T	NONSYN	757	759	TGG	1018	1020	ACG	229;230;236	A;C,T;G	210;211,1;216	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1021	1023	AGG	235;232;231	A;G,T;G	215;213,1;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	A255V	NONSYN	763	765	GCT	1024	1026	GTT	234;234;233	G;T;T	215;212;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1084	1086	GTA	256;255;257	G;T;A	233;231;233	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1123	1125	ACT	273;272;276	A;C;T	247;246;254	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1129	1131	GAT	275;273;274	G;A;T	250;246;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1132	1134	GAT	273;272;269	G;A;T	248;248;251	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1138	1140	AAC	268;268;267	A,G;A;C,A	255,1;253;253,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1141	1143	CAC	270;269;271	C,A;A;C	256,1;253;254	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1246	1248	GAC	281;278;277	G;A;C	257;253;256	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	1	SNP	p	G120K	0	.	.	358	360	GGT	613	615	GGT	251;249;252	G;G;T	227;226;227	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	1	SNP	p	A121N	0	.	.	361	363	GCC	616	618	GCC	251;251;251	G;C;C	230;231;230	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3186	porB1b	1035	1035	96.45	porB1b.l15.c17.ctg.1	1434	220.5	1	SNP	p	A121D	0	.	.	361	363	GCC	616	618	GCC	251;251;251	G;C;C	230;231;230	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12842	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4815	266.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1998	2000	AAT	301;299;298	A;A;T	279;277;274	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1466	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	967	149.7	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	322;317;320	A;T;G	306;303;304	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
